Page last updated: 2024-09-03

3-(2,4-dimethoxybenzylidene)anabaseine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

3-(2,4-dimethoxybenzylidene)anabaseine has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 1 studies

Compound Research Comparison

Studies
(3-(2,4-dimethoxybenzylidene)anabaseine)
Trials
(3-(2,4-dimethoxybenzylidene)anabaseine)
Recent Studies (post-2010)
(3-(2,4-dimethoxybenzylidene)anabaseine)
Studies
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
Trials
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
Recent Studies (post-2010) (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
1668813,85981,052

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Kang, JL; Kim, DY; Kim, HS; Leem, YH; Park, JE; Park, JS1

Other Studies

1 other study(ies) available for 3-(2,4-dimethoxybenzylidene)anabaseine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

ArticleYear
Anti-Inflammatory and Neuroprotective Mechanisms of GTS-21, an α7 Nicotinic Acetylcholine Receptor Agonist, in Neuroinflammation and Parkinson's Disease Mouse Models.
    International journal of molecular sciences, 2022, Apr-16, Volume: 23, Issue:8

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Anti-Inflammatory Agents; Benzylidene Compounds; Disease Models, Animal; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Microglia; Neurodegenerative Diseases; Neuroinflammatory Diseases; Neuroprotective Agents; NF-kappa B; Nicotinic Agonists; Parkinson Disease; Phosphatidylinositol 3-Kinases; Pyridines

2022